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Background: Several guidelines on infection control and treatment of infection exist for cystic fibrosis (CF) caregivers, although the extent of
implementation is variable.
Methods: Adherence to European Consensus Guidelines for CF was studied by sending surveys to named healthcare professionals in 487
European CF centres/units. Qualitative data analysis was performed.
Results: A total of 177/547 (32%) surveys were returned. Infection control policies were implemented by most (77%) respondents. Separation of
patients with Burkholderia cepacia was more common in adults (95%) than children (9%), and was implemented by 53% of respondents for
Pseudomonas aeruginosa. Nebulised colistin plus oral ciprofloxacin was the most common (43%) therapy for P. aeruginosa infection. First
infections of P. aeruginosa were usually treated with inhaled tobramycin; 41% of repondents did not intervene until lung function deteriorated.
Most exacerbations were treated for less than the recommended period.
Conclusions: European Consensus Guidelines are widely adhered to. Areas for improvement include: initiating therapy for exacerbations early,
separating infected patients and optimising duration of antibiotic therapy.
© 2009 Published by Elsevier B.V. on behalf of European Cystic Fibrosis Society.Keywords: Cystic fibrosis; Infection; Pseudomonas aeruginosa; Survey; European1. Introduction
The primary cause of death and long-term complications
among people with cystic fibrosis (CF) is chronic bacterial
infection [1,2]. Chronic infection contributes to a decline in
forced expiratory volume in 1 s (FEV1) of approximately 2%
per year [3]. Chronic pulmonary infection in people with CF is
caused by a limited number of microbial pathogens of which the
most common species are Pseudomonas aeruginosa, Staphylo-
coccus aureus, Haemophilus influenzae and the Burkholderia
cepacia complex [4–6].
Pulmonary exacerbations can damage a patient's lung tissue
and, in people with CF, there is a clear correlation between the⁎ Corresponding author: Belfast City Hospital, Ground Floor, Lisburn Road,
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doi:10.1016/j.jcf.2009.03.001number of exacerbations per year and patient age. Exacerba-
tions are most common in the adolescent and adult population
with nearly 50% of patients, between the ages of 18 and
30 years, experiencing at least one exacerbation per year
[7]. This contrasts with those under 10 years of age of whom
75–85% remain exacerbation free. Recurring exacerbations
cause further lung damage and are associated with poorer
outcomes [2]. By early adulthood, most people with CF have
evidence of lung function impairment (as measured by FEV1)
[8], which is seen to decline to 64% of that predicted. This lung
damage is moderate in a large proportion of patients (40%),
compared with mild (25%) or no impairment (13%) in a smaller
proportion of patients [9].
The European Cystic Fibrosis Society Consensus Guidelines
[2] defined appropriate standards of care with the aim of
bringing an element of uniformity to the management of
patients with CF, something that had been lacking previouslyropean Cystic Fibrosis Society.
Fig. 1. Point of intervention with nebulized antibiotics following infection with
Pseudomonas aeruginosa (multiple responses possible per respondent).
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centre, outline the recommended roles and responsibilities of
individual members of the multidisciplinary team, and provide a
framework of routines in CF care. These guidelines include
optimal recommendations for the prevention and treatment of
infection with pathogens such as P. aeruginosa. To determine
the uptake of these standards of care and to explore the
treatment of P. aeruginosa across Europe, a pan-European
survey was undertaken to gather views from named respondents
who were CF specialists within CF centres across Europe.
2. Methods
A survey was developed and distributed in 2005–2006 to
547 participating CF centres across 32 European countries. The
methodology and survey questionnaire (which included both
open and directed questions) are described in the companion
manuscript by Elborn et al. [13]. This report specifically
addresses the awareness and adherence of CF centres to
guidance relating to the treatment and management of infections
in CF patients, in order to obtain important insights into
differences in infection control procedures and the management
of pulmonary infection in CF patients across Europe.
3. Results
Of the 547 surveys distributed, 177 were completed and
returned (32% response rate), providing data on 21,172 patients.
Details of the geographical spread and results relating to the
healthcare teams and access to care are presented in the
companion manuscript by Elborn et al. [13]. It is important to
note that there was a large variation in the number of patients
cared for in different centres, which may result in differences in
practice: 55% of centres cared for between 1 and 100 patients;
31% of centres cared for between 101 and 750 patients; and
14% of centres cared for 200–750 patients.
Of the 177 respondents, most (79%) were able to identify
and manage infection by working with colleagues such as
specialist microbiologists. Access to most specialists was, on
the whole, similar for respondents treating either children or
adults. Specialist microbiologists were, however, available for a
larger percentage of adult patients (95%) than paediatric
patients (67%).
3.1. Infection control
In common with other guidelines [10], the European
Consensus Guidelines of 2005 [2] recommend the provision
and implementation of clear infection control policies, as
patients are at particular risk of harbouring multiresistant
organisms (e.g. methicillin-resistant S. aureus [MRSA], P.
aeruginosa and B. cepacia) [10], thus presenting a risk to
themselves and other vulnerable patients. Results from this
survey suggest that most respondents (77%) had current written
infection control policies and were aware of, and had read, the
consensus guidelines.Most centres separated outpatients (all age groups) who were
infected with B. cepacia complex organisms (93%), MRSA
(85%), multiresistant Pseudomonas spp. (69%) and non-
pseudomonal infection (68%). Fewer centres (29%) separated
outpatients infected with Pseudomonas subtypes (multiresistant
or clonal strains). During inpatient care, patients with different
genera of bacteria were commonly separated (91% with B.
cepacia complex organisms, 89% with MRSA, 77% with non-
pseudomonal infection), although pseudomonal subtypes were
separated less frequently (53%). Within wards, less separation
was seen with only 53% of respondents routinely separating
patients infected with Pseudomonas subtypes. When inpatient
data were analysed by age group, a large difference was seen in
the number of children with B. cepacia complex infections
routinely separated (9%) compared with adults (95%); no
notable differences were seen for other pathogens. This is in
contrast to the 2005 recommendations which stipulate that all
patients infected with B. cepacia should be separated from each
other, because of the varying virulence of various B. cepacia
complex genomovars [2]. By contrast, in line with current
recommendations and current inpatient practice, more than 90%
of respondents performed outpatient consultations separately
for those patients who were colonised with B. cepacia complex.
Only 29% of centres had separate clinics for those patients
chronically infected with P. aeruginosa.
Most respondents (96%) carried out routine antibiotic
sensitivity testing to assist them in making an antibiotic
prescribing decision. A total of 90% of respondents tested for
the presence of B. cepacia complex organisms in sputum, 89%
always obtained a sputum or throat swab and 67% provided
minimum inhibitory concentration testing. Slightly fewer (44%)
provided synergy testing or routinely monitored P. aeruginosa
antibodies (41%).3.2. Management of pulmonary infection
Of the 96% of respondents who carried out tests, the
outcome of routine in-vitro testing prompted the prescribing
decision for 94%. Overall (all age groups), the overriding aim of
Fig. 2. Antibiotic treatment regimens employed by respondents in order to treat or eradicate Pseudomonas aeruginosa.
Fig. 3. Treatment strategies for a) intermittent Pseudomonas aeruginosa infection, and b) chronic P. aeruginosa infection.
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Fig. 4. Indication for initiating treatment for Staphylococcus aureus, as
highlighted by survey respondents.
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suppress chronic bacterial infection (29%) and reduce the need
for intravenous antibiotics (21%). Few respondents viewed
eradication of infection as the most important aim (14%). When
stratified by age, however, eradication of P. aeruginosa was the
primary goal for more respondents who treated children (16%)
than for those who treated adults (5%). Conversely, reducing the
need for intravenous antibiotic treatment was prioritised by
fewer respondents who treated children (22%) than those who
treated adults (35.0%).
Almost all respondents treated the first P. aeruginosa
infection with antibiotics and most used nebulised antibiotics.
However, a substantial proportion of respondents did not
institute antibiotic therapy unless P. aeruginosa was isolated
repeatedly or lung function had deteriorated (Fig. 1). The most
common approaches to treating or eradicating P. aeruginosa
infection included nebulised tobramycin (41%) or nebulised
colistin in conjunction with oral ciprofloxacin (43%) (Fig. 2). A
small percentage of respondents (1%) used a prophylactic
approach to P. aeruginosa infection by implementing therapy at
CF diagnosis (Fig. 1), and a notable number of respondents
(34%) implemented therapy with oral ciprofloxacin alone
(Fig. 2).
Intermittent P. aeruginosa infections were treated with
nebulised tobramycin by 46% of respondents although, as
noted previously, many respondents also used nebulised colistin
with oral ciprofloxacin (38%) or oral ciprofloxacin alone (31%).
A small percentage (4%) adopted a more passive strategy,
observing patient progress without introducing antibiotic
therapy. This mirrors treatment patterns seen for treatment/
eradication strategies (Fig. 3a). In chronic infection, tobramycin
and colistin were the most commonly used agents (each agent
used by 54%). Fewer respondents used nebulised intravenous
preparations of tobramycin, gentamicin delivered via nebuliser
or other antibiotics, such as ceftazidime (Fig. 3b).
For intravenous treatment of acute infections, 70% of
respondents used combination therapies, compared with 33%
who used combination therapy plus a nebulised antibiotic. A
total of 74% of centres used oral antibiotics to treat acute
P. aeruginosa infections. Disparity in the length of treatment
with oral antibiotics was seen: most centres treated patients for
either 9 days or less, or 10–14 days (Table 1); and a smaller
percentage treated patients for more than 14 days, which is
recommended by several authors [10,12,14]. Small differences
between adults and children were observed in length of
treatment, with fewer children being treated for more than
10 days. When intravenous antibiotics were used to treat acuteTable 1
Duration of treatment of acute infective exacerbations of Pseudomonas
aeruginosa infection with oral antibiotics.




Not applicable 15.8exacerbations, 69% of respondents treated for 10–14 days and
33% treated for more than 14 days; no respondents treated for
less than 10 days. In a recent review [14], a drug formulary
to treat P. aeruginosa has been developed that recommends a
2-week course of intravenous treatment with tobramycin and
ceftazidime.
Most respondents (68%) initiated therapy for S. aureus
infection at the point at which lung function had deteriorated as
a consequence, or in response to, repeated S. aureus infections.
Among other respondents, 35% initiated therapy at first
infection and 16% at diagnosis of CF (Fig. 4). The
most common treatment duration for S. aureus infection was
2–4 weeks (55% of respondents), with only 11% treating for
more than 4 weeks.
4. Discussion
P. aeruginosa is the most common bacteria to infect the
lungs of individuals with CF and is present in up to 80% of
patients aged 25–35 years [7]. P. aeruginosa infection is
associated with increased morbidity in patients with CF. In
particular, it leads to faster deterioration in lung function [15,16]
and thus more severe disease [17]. Patients with P. aeruginosa
infections experience reduced lung function [18], poor growth
[16] and reduced life expectancy [19]. Other consequences of
infection include an increased need for antibiotic therapy [20]
and a greater likelihood of hospitalisation [21]. Infections with
P. aeruginosa contribute to an annual deterioration in lung
function of up to 2% and up to 90% of infected patients will die
of lung disease [3].
Although rates of infection with B. cepacia complex
(approximately 10% among 25–34 year-olds) are lower than
those for P. aeruginosa in patients with CF [22], the infection is
particularly problematic in this group. B. cepacia infections
lead to a significantly greater increase in the decline in lung
function and a significantly greater reduction in body mass
index than those caused by P. aeruginosa infections [23].
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resistance, a high transmission rate and carries the risk of
causing ‘cepacia syndrome’. This fulminating pneumonia is
accompanied by septicaemia in approximately 20% of patients
colonised, including those who have previously only suffered
from mild disease [24].
As chronic infection is key to the increased morbidity in
patients with CF, the goal of infection control is to prevent
pathogens such as P. aeruginosa or B. cepacia complex from
becoming permanently established. One approach has been to
employ antibiotic treatment to prevent or delay the establish-
ment of chronic P. aeruginosa infection with the intention of
preventing or reducing lung deterioration, and improving
survival [20]. The use of prophylaxis has shown variable
success, with some units presenting lower rates of P. aeruginosa
infection than the national average as a result [25]. However, for
prophylaxis to be successful, patients must adhere to therapy,
and exacerbations are often the result of reduced compliance or
failure to adhere to therapy [26].
Antibiotic strategies that have become commonly used to
treating exacerbations include intravenous [25] or inhaled
antibiotics direct to the point of infection [3,27], either
electively or with an observed change in clinical symptoms
[10]. Indeed, early use of nebulised antibiotics or a combination
of nebulised and oral antibiotics is recommended by some
authorities in an attempt to delay chronic infection and
ultimately respiratory deterioration [10]. Chronic P. aeruginosa
infections are often treated using nebulised colistin [28],
although newer antibiotics such as tobramycin are increasingly
being used – a practice supported by results from studies of
intermittent administration [3]. Quinolones, including cipro-
floxacin, are one of the few classes of orally active drugs with
anti-pseudomonal activity [14]. However, in the UK, a
resistance rate to ciprofloxacin of 30% has been observed,
which means that the only option for a second antibiotic in such
patients is nebulised tobramycin or colistin [14].
Regardless of the mode of administration, treatment of
pulmonary exacerbations in patients chronically infected with
P. aeruginosa has been demonstrated to improve FEV1 and,
in so doing, reduce hospitalisations.
It is encouraging to find that guidelines developed by the
Consensus panel and published in 2005 [2] are being followed to a
high degree throughout Europe and that, in many respects, no
differences due to the geographical location of respondents are
observed. The implementation of clear infection control policies
is vital for the control of cross-infection in vulnerable CF patients,
as every pulmonary infection can cause further lung damage [3].
The survey indicates that the impact of infection is taken seriously,
with most participating centres having written infection control
policies that are being adhered to. However, with 23% of
respondents not implementing a written policy for dealing with
infection, there is still clearly a need for improvement.
The recent European Consensus Guidelines highlight the
importance of separating patients with or without P. aeruginosa
infections [2]. While it is commendable that most Pseudomo-
nas-infected patients (75–93%) are separated from non-infected
patients, some improvements could still be made. The EuropeanConsensus Guidelines recommend that, in order to minimise
cross-infection, beds for patients with CF should be contained in
single rooms (which have the additional advantage of facilitat-
ing inhaled antibiotic therapy), ideally according to a patient's
microbiological status including Pseudomonas subtypes [2].
Such segregation is valuable, especially if epidemic strains are
involved. Despite this, only around 50% of respondents
routinely separated their inpatients and less than 30% routinely
separated outpatients according to Pseudomonas subtype.
Microbiological testing and consultation with specialist
colleagues was carried out by 79% of respondents. These data
are encouraging as the complicated microbiology of patients
with CF necessitates specialised knowledge and expertise to
avoid misdiagnosis, as well as an understanding of how to treat
identified pathogens appropriately. While the rates of consulta-
tion with specialist colleagues were encouraging, some gaps
were identified in specific microbiological screening. Most
respondents (89%) always obtained a sputum or throat swab
from their patients, but the percentage who monitored for P.
aeruginosa antibodies (41%) was considerably lower. This
contrasts with the European Consensus Guidelines [2] and a
European consensus report [12], which recommend that regular
monitoring should occur. Both publications recommend that
patients are seen at least every 3 months, or ideally every month,
and that microbiological samples are obtained.
More than 96% of respondents carried out tests to identify the
colonising bacteria and, where appropriate, to evaluate bacter-
ium susceptibility. Furthermore, the vast majority of antibiotic
prescribing was based on the test results in a bid to circumvent
possible antimicrobial resistance that may occur due to the
frequent use of antibiotics by patients [2]. It is reassuring to see
that most centres are treating P. aeruginosa infection aggres-
sively and that, generally, centres across Europe are treating in
accordance with the European Consensus Guidelines [2]. As
outlined in the guidelines, the therapeutic aim is chronic
bacterial suppression, and this can be achieved by intensive
and early use of antibiotics to eradicate the first and/or
intermittent P. aeruginosa colonisation in all age groups [2].
For the treatment of chronic P. aeruginosa infection, tobramycin
and colistin are most commonly used. However, across Europe,
nebulised tobramycin now appears to be the most common
treatment for intermittent infection with P. aeruginosa, with
fewer respondents prescribing nebulised colistin and oral
ciprofloxacin. This is in line with guidelines that recommend
the chronic use of inhaled tobramycin in patients over 6 years of
age who have moderate-to-severe lung disease and P. aerugi-
nosa infection; or who are asymptomatic or have mild lung
disease and P. aeruginosa persistently present in cultures of
airway secretions. A recent study evaluated levels of tobramycin
and ceftazidime in serum and sputum samples, and investigated
the susceptibility of cultured bacteria to intravenous mono-
therapy and combination therapy [29]. More than half of the P.
aeruginosa isolates were susceptible to ceftazidime and
tobramycin, and combining ceftazidime and tobramycin was
synergistic against more than three-quarters of isolates.
As well as the type of treatment given, the point at which it is
initiated is important. In the current survey, 41% of respondents
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deteriorated. Consensus guidelines state that “early intervention
and prevention of lung disease is of paramount importance” and
that early or prophylactic antibiotic therapies have a role in
influencing the outcome for the patient [12]. This suggests that
clinicians may not be treating CF infections as early or
aggressively as the guidelines advise.
While infection control and approaches to treatment were
broadly similar for adults and children, some differences were
seen. Respondents indicated that access to specialist micro-
biologists was greater for adult patients than paediatric patients.
Preventing cross-infection by B. cepacia complex also appeared
to be prioritised in adults compared with children (95% of adults
were separated vs 9% of children). Age-related treatment
differences were also seen with eradication of P. aeruginosa
prioritised more in children than adults (16% vs 5%).
While this survey provides good insights into current
practice and sheds light on how bacterial infections are
managed in the population with CF, it is subject to the same
limitations as similar surveys. Responses to the survey are more
likely to have come from centres already implementing the
European Consensus Guidelines, therefore, it may overestimate
adherence. It is possible that those centres not responding
deliver a different standard of care and that the reported findings
are over-optimistic. In addition, geographical (Eastern vs
Western Europe) similarities in standards of care should be
interpreted with caution because of the low number of responses
from Eastern Europe. It is possible that only those centres
offering the highest quality care or those with English-speaking
staff returned questionnaires.
It is difficult to determine the total number of people with CF
in Europe, but a demographic survey undertaken Eurocare-CF
estimates the number to be approximately 30,000 [30]. Thus,
this survey reflects the care provided for around 80% of patients
in Europe with CF. A key finding of the survey is the apparent
variation in the management of first infections in these patients.
Other areas where there is variation in patient care include early
initiation of initiating therapy for exacerbations, separation of
bacterially infected patients, and optimisation of the duration of
antibiotic therapy. In order to supply consistent, high quality
care, it is important that the directors of CF centres and shared-
care clinicians are fully educated and familiar with the European
Consensus Guidelines, and are provided with the necessary
resources to implement them.
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